SBC Medical Launches Translation App Specialized Medical Aesthetics and Strengthens "Inbound-Focused Clinics" Initiative
20.1.2025 13:00:00 CET | Business Wire | Press release
– Pioneering a New Era Where Global Patients Can Embrace Beauty and Confidence Through Japan's Cutting-Edge Medical Aesthetics –
Shonan Beauty Clinic, supported by SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical,” or the “Company”) in management services, today announced the launch of its proprietary translation app tailored for medical aesthetics staff and the full-scale implementation of its "Inbound-Focused Clinics" initiative. This groundbreaking move is designed to address the growing demand for medical tourism and ensure that international patients can seamlessly experience Japan's advanced medical aesthetic treatments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250120588355/en/
Shonan Beauty Clinic, supported by SBC Medical Group Holdings Incorporated (Nasdaq: SBC) in management services, today announced the launch of its proprietary translation app tailored for medical aesthetics staff and the full-scale implementation of its "Inbound-Focused Clinics" initiative. This groundbreaking move is designed to address the growing demand for medical tourism and ensure that international patients can seamlessly experience Japan's advanced medical aesthetic treatments. (Photo: Business Wire)
Capitalizing on Medical Tourism’s Expanding Opportunities
The global medical aesthetics market is projected to grow at a compound annual growth rate (CAGR) of 12.17% from 2024, reaching $212.5 billion by 2032. Within Asia, rising awareness of aesthetic care and the increasing appeal of medical tourism are positioning countries like Japan, South Korea, and Thailand as top destinations for international patients. In Japan, the influx of foreign patients seeking high-quality medical aesthetics continues to rise. SBC alone welcomes over 10,000 inbound patients annually, with inquiries surpassing 20,000 each year. China remains a key market driver, though demand from English-speaking regions is also on the rise. Recognizing this trend, SBC is scaling up its operational capacity and implementing innovative solutions to support sustainable growth in this dynamic sector.
Revolutionizing Communication with a Specialized Translation App
To address language barriers, SBC has developed a state-of-the-art translation app tailored specifically for medical aesthetics. This app ensures the accurate translation of specialized terminology, facilitating seamless communication between clinic staff and international patients. Currently supporting English and Chinese, the app plays a pivotal role in enabling smooth consultations and pre-treatment explanations. By creating a welcoming environment where language is no obstacle, SBC empowers patients to feel secure and confident in their treatment choices. Future plans include expanding the app's language capabilities and rolling it out across all clinics nationwide, ensuring comprehensive accessibility for a global clientele.
"Inbound-Focused Clinics" to Drive Regional Development
SBC has designated three flagship locations – Shinjuku Main Clinic, Shinbashi-Ginza Clinic, and Osaka Umeda Clinic – as "Inbound-Focused Clinics." These facilities are staffed with dedicated English- and Chinese-speaking concierges, ensuring seamless, trustworthy communication. To further enhance accessibility, SBC plans to extend this initiative to key cities including Yokohama, Nagoya, Sendai, and Sapporo. With these measures in place, the company aims to double its annual inbound patient volume to 20,000 by this year.
A Vision for the Future: Medical Tourism as a "Beauty Infrastructure"
SBC’s mission transcends the delivery of aesthetic treatments. It strives to offer patients an unparalleled experience of "beauty" and "confidence" – values deeply rooted in Japan’s culture and technological excellence. By combining state-of-the-art medical aesthetics with the renowned warmth of Japanese hospitality, SBC is setting a new standard for tourism where healthcare, beauty, and culture intersect. This initiative not only boosts inbound tourism but also plays a vital role in regional revitalization and the broader growth of Japan’s medical tourism sector. Through its commitment to "delivering beauty beyond medicine," SBC continues to redefine the global landscape of medical aesthetics and inspire patients worldwide.
About SBC Medical
SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics.
For more information, visit https://sbc-holdings.com/
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250120588355/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
Cyviz: Microsoft’s Immersive Approach to Collaboration12.6.2026 09:00:00 CEST | Press release
At Microsoft’s Innovation Hub in Amsterdam, immersive technology is used to enable co-creation rather than one-way presentations. In the company’s Immersive Suite, customers, data experts, and technology specialists come together in a shared environment to address complex challenges more effectively. Watch Video Case Study >> This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612831180/en/ Watch Video Case Study >> https://www.cyviz.com/case-studies/microsoft-immersive-suite/ As business and technology environments grow more complex, establishing shared understanding across disciplines has become critical. The Immersive Suite is designed for active collaboration, where visual narratives, data, and technical content are explored interactively. This allows participants to test scenarios, align perspectives, and move more efficiently from discussion to decision. “We deliberately work with familiar tools like PowerPoint. That all
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom